Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) had its price objective lowered by HC Wainwright from $10.00 to $4.00 in a report published on Wednesday, The Fly reports. The firm currently has a buy rating on the biotechnology company’s stock.
TRIL has been the topic of a number of other reports. ValuEngine lowered Trillium Therapeutics from a hold rating to a sell rating in a research report on Tuesday, December 25th. Zacks Investment Research lowered Trillium Therapeutics from a buy rating to a hold rating in a research report on Wednesday, November 21st. Finally, Cowen restated a buy rating on shares of Trillium Therapeutics in a research report on Thursday, December 20th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Trillium Therapeutics presently has an average rating of Hold and a consensus price target of $4.67.
NASDAQ TRIL opened at $0.60 on Wednesday. The company has a market cap of $10.06 million, a P/E ratio of -0.25 and a beta of 2.31. Trillium Therapeutics has a one year low of $0.55 and a one year high of $8.40. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.33 and a current ratio of 3.56.
Trillium Therapeutics Company Profile
Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies, and solid tumors and mycosis fungoides.
See Also: Dividend Aristocrat Index
Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.